Income Statement
ACRIVON THERAPEUTICS, INC.
ACRV
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY |
|---|---|---|---|---|
|
Revenue
|
- | - | - | - |
|
Cost of Revenue
|
- | - | - | - |
|
Gross Profit
|
- | - | - | - |
|
Operating Expenses
|
84.11 | 89.20 | 67.10 | 32.66 |
|
Research & Development
|
59.99 | 63.99 | 46.02 | - |
|
Selling, General & Administrative
|
24.12 | 25.21 | 21.08 | - |
|
Other Operating Expenses
|
- | - | - | - |
|
Operating Income
|
-84.11 | -89.20 | -67.10 | -32.66 |
|
Non-Operating Income
|
6.21 | 8.64 | - | 1.49 |
|
Interest Income
|
- | - | 7.00 | - |
|
Interest Expense
|
- | - | - | - |
|
Other Non-Op Income / Expense
|
-0.27 | -0.56 | 6.72 | 1.49 |
|
Income Before Tax
|
-77.83 | - | - | - |
|
Income Tax Expense
|
- | - | - | - |
|
Non-Controlling Interest
|
- | - | - | - |
|
Net Income
|
-77.91 | -80.56 | -60.39 | -31.17 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY |
|---|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - | - |
|
EBITDA
|
-84.11 | -89.20 | -67.10 | -32.66 |
|
Earnings Per Share (Basic)
|
-2.02 | -2.38 | -2.74 | -7.56 |
|
Diluted EPS
|
-2.02 | -2.38 | -2.74 | -7.56 |
|
Weighted Average Shares
|
38.51 | 33.79 | 22.08 | 4.12 |
|
Diluted Weighted Avg Shares
|
38.51 | 33.79 | 22.08 | 4.12 |
|
Comprehensive Income
|
-78.24 | -80.03 | -60.38 | - |